These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 23969222)

  • 21. Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions.
    Fan L; Chen LL; Lin CG; Peng YF; Zheng XC; Luo YK; Zhang FL; Chen JH; Yan XP; Huang ZR
    Chin Med J (Engl); 2008 Aug; 121(16):1518-23. PubMed ID: 18982862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of biodegradable polymer versus durable polymer sirolimus-eluting stenting in patients with acute st-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the RESOLVE study.
    Zhang Q; Qiu JP; Kirtane AJ; Zhu TQ; Zhang RY; Yang ZK; Hu J; Ding FH; DU R; Shen WF
    J Interv Cardiol; 2014 Apr; 27(2):131-41. PubMed ID: 24697948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
    Chen SL; Ye F; Zhang JJ; Zou JJ; Qian XS; Li F; Yang S; Ge Z; Shan SJ; Li XB; Xu T; Kan J; Lin L; Han YL
    Cardiovasc Ther; 2013 Aug; 31(4):193-200. PubMed ID: 22954234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial.
    Morice MC; Serruys PW; Barragan P; Bode C; Van Es GA; Stoll HP; Snead D; Mauri L; Cutlip DE; Sousa E
    J Am Coll Cardiol; 2007 Oct; 50(14):1299-304. PubMed ID: 17903626
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study.
    Cassese S; De Luca G; Villari B; Berti S; Bellone P; Alfieri A; Montinaro A; Quaranta G; Marraccini P; Piscione F;
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):408-16. PubMed ID: 21735531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sirolimus- versus paclitaxel-eluting stents for coronary bifurcations intervention: a meta-analysis of five clinical trials.
    Qian J; Chen Z; Ma J; Ge J
    Catheter Cardiovasc Interv; 2012 Oct; 80(4):507-13. PubMed ID: 22045690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents.
    Byrne RA; Mehilli J; Iijima R; Schulz S; Pache J; Seyfarth M; Schömig A; Kastrati A
    Eur Heart J; 2009 Apr; 30(8):923-31. PubMed ID: 19240066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors predictive of cardiac events and restenosis after sirolimus-eluting stent implantation in small coronary arteries.
    Lee CW; Suh J; Lee SW; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2007 May; 69(6):821-5. PubMed ID: 17191211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes in patients with renal impairment undergoing percutaneous coronary intervention and implantation of the Endeavor zotarolimus-eluting stent: 1- and 2-year data from the E-Five Registry.
    Rothman MT; Jain AK;
    Catheter Cardiovasc Interv; 2012 Nov; 80(6):885-92. PubMed ID: 22517785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term outcomes of routine versus provisional T-stenting for de novo coronary bifurcation lesions: five-year results of the Bifurcations Bad Krozingen I study.
    Ferenc M; Ayoub M; Büttner HJ; Gick M; Comberg T; Rothe J; Valina CM; Hochholzer W; Neumann FJ
    EuroIntervention; 2015 Dec; 11(8):856-9. PubMed ID: 26696453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence, time course and predictors of early vs. late target lesion revascularisation after everolimus-eluting stent implantation: a SPIRIT V substudy.
    Niccoli G; Stuteville M; Sudhir K; Li D; Montone RA; Bolognese L; Grube E
    EuroIntervention; 2013 Jul; 9(3):353-9. PubMed ID: 23482242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Five-year clinical follow-up after implantation of the Endeavor zotarolimus-eluting stent: ENDEAVOR I, first-in-human study.
    Meredith IT; Ormiston J; Whitbourn R; Kay IP; Muller D; Cutlip DE;
    Catheter Cardiovasc Interv; 2009 Dec; 74(7):989-95. PubMed ID: 19859958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Right coronary artery 'diverticulosis' 4 years after sirolimus-eluting stent implantation associated with very late stent thrombosis.
    Good RI; Kalra S; Lee TC
    Heart; 2013 Nov; 99(21):1627. PubMed ID: 23749781
    [No Abstract]   [Full Text] [Related]  

  • 35. First-in-human evaluation of a sirolimus-eluting coronary stent on an integrated delivery system: the DIRECT study.
    Webster M; Harding S; McClean D; Jaffe W; Ormiston J; Aitken A; Watson T
    EuroIntervention; 2013 May; 9(1):46-53. PubMed ID: 23685294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized study comparing everolimus- and sirolimus-eluting stents in patients with bifurcation lesions treated by provisional side-branch stenting.
    Pan M; Medina A; Suárez de Lezo J; Romero M; Segura J; Martín P; Suárez de Lezo J; Hernandez E; Mazuelos F; Ojeda S
    Catheter Cardiovasc Interv; 2012 Dec; 80(7):1165-70. PubMed ID: 22511299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction 3-year results of the SESAMI (sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction) trial.
    Violini R; Musto C; De Felice F; Nazzaro MS; Cifarelli A; Petitti T; Fiorilli R
    J Am Coll Cardiol; 2010 Feb; 55(8):810-4. PubMed ID: 20170821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial.
    Jiménez-Quevedo P; Sabaté M; Angiolillo DJ; Alfonso F; Hernández-Antolín R; SanMartín M; Gómez-Hospital JA; Bañuelos C; Escaned J; Moreno R; Fernández C; Fernández-Avilés F; Macaya C;
    Eur Heart J; 2007 Aug; 28(16):1946-52. PubMed ID: 17562666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paclitaxel- and sirolimus-eluting stents in older patients with diabetes mellitus: results of a real-life multicenter registry.
    Buja P; Facchin M; Musumeci G; Frigo AC; Saia F; Menozzi A; Meliga E; Sardella G; Tamburino C; Tarantini G
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1117-24. PubMed ID: 22936398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and angiographic experience with a third-generation drug-eluting Orsiro stent in the treatment of single de novo coronary artery lesions (BIOFLOW-I): a prospective, first-in-man study.
    Hamon M; Niculescu R; Deleanu D; Dorobantu M; Weissman NJ; Waksman R
    EuroIntervention; 2013 Jan; 8(9):1006-11. PubMed ID: 23339805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.